Convalescent plasma therapy in aHUS patient with SARS-CoV-2 infection
Article Sidebar
Main Article Content
Abstract
Endotheliosis, thrombotic microangiopathy and complement system over activation have been described as pathologic features of tissue damage in the setting of coronavirus disease. Interestingly, complement-mediated cell injury is also a typical feature of atypical Hemolytic Uremic Syndrome. Indeed, a growing body of literature has described a higher risk of microangiopathy recurrence, in aHUS patients who test positive for SARS-CoV-2. The correct clinical and therapeutic management patients with a history of HUS and SARS-CoV-2 infection is not well established.
We report a case of SARS-CoV-2 infection in an aHUS patient who did not develop a recurrence of the disease and that was successfully treated with convalescent immune plasma therapy.
Article Details
Copyright (c) 2022 Stea ED, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Journal of Clinical Nephrology is committed in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. In order to use the Open Access paradigm to the maximum extent in true terms as free of charge online access along with usage right, we grant usage rights through the use of specific Creative Commons license.
License: Copyright © 2017 - 2025 | 
Open Access by Journal of Clinical Nephrology is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at Heighten Science Publications Inc.
With this license, the authors are allowed that after publishing with the journal, they can share their research by posting a free draft copy of their article to any repository or website.
Compliance 'CC BY' license helps in:
| Permission to read and download | ✓ |
| Permission to display in a repository | ✓ |
| Permission to translate | ✓ |
| Commercial uses of manuscript | ✓ |
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
Noris M, Benigni A, Remuzzi G. The case of complement activation in COVID-19 multiorgan impact. Kidney Int. 2020; 98: 314-322. PubMed: https://pubmed.ncbi.nlm.nih.gov/32461141/
Zipfel PF, Wiech T, Stea ED, Skerka C. CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. J Am Soc Nephrol. 2020; 31: 241-256. PubMed: https://pubmed.ncbi.nlm.nih.gov/31980588/
Petrungaro A, Quartarone E, Sciarrone P. Anti-SARS-CoV-2 hyperimmune plasma workflow. Transfus Apher Sci. 2020; 59: 102850. PubMed: https://pubmed.ncbi.nlm.nih.gov/32540345/
Cusi MG, Conticini E, Gandolfo C, Anichini G, Savellini GG, et al. Hyperimmune plasma in three immuno-deficient patients affected by non-severe, prolonged COVID-19: a single-center experience. BMC Infect Dis. 2021; 21: 630. PubMed: https://pubmed.ncbi.nlm.nih.gov/34210259/
Ville S, Le Bot S, Chapelet-Debout A, Blancho G, Fremeaux-Bacchi V, et al. Atypical HUS relapse triggered by COVID-19. Kidney Int. 2021; 99: 267-268. PubMed: https://pubmed.ncbi.nlm.nih.gov/33188793/
Yu J, Yuan X, Chen H, Chaturvedi S, Braunstein EM, et al. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood. 2020; 136: 2080-2089. PubMed: https://pubmed.ncbi.nlm.nih.gov/32877502/
Maharaj N, Sankat S, Spann J, Goorachan S, Sookoo A. POS-041 Haemolytic Uremic Syndrome (HUS) with Covid-19 infection: 2 case reports. Is there a direct link? Kidney Int Rep. 2021; 6: S18–19. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049736/
Jhaveri KD, Meir LR, Flores Chang BS, Parikh R, Wanchoo R, et al. Thrombotic microangiopathy in a patient with COVID-19. Kidney Int. 2020; 98: 509-512. PubMed: https://pubmed.ncbi.nlm.nih.gov/32525010/
Trimarchi H, Gianserra R, Lampo M, Monkowski M, Lodolo J. Eculizumab, SARS-CoV-2 and atypical hemolytic uremic syndrome. Clin Kidney J. 2020; 13: 739-741. PubMed: https://pubmed.ncbi.nlm.nih.gov/33117528/